2-ethyl-7-methyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-ethyl-7-methyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide
• 化学式: C₃₀H₃₁F₃N₄O₂
• 分子量: 536.6
• InChiKey: LMLOYIPFMSMPGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.9
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• ANTI-INFECTIVE COMPOUNDS
  申请人：Institut Pasteur Korea

  公开号：EP3027615B1

  公开（公告）日：2021-07-21
• Anti-Infective Compounds
  申请人：INSTITUT PASTEUR KOREA

  公开号：US20160185774A1

  公开（公告）日：2016-06-30

  The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
• A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
  申请人：Shionogi & Co., Ltd.

  公开号：US20220235047A1

  公开（公告）日：2022-07-28

  The present invention relates to novel combinations. The invention also relates to such combinations for use as pharmaceuticals, for instance in the treatment of bacterial diseases, including diseased caused by pathogenic mycobacteria such as non-tuberculosis mycobacteria. In particular, the present invention relates to a medicament, characterized in that a compound having a cytochrome bc1 inhibitory activity, or its pharmaceutically acceptable salt, is combined with clarithromycin or azithromycin, and clofazimine, or their pharmaceutically acceptable salts.